Steward Partners Investment Advisory’s Protalix BioTherapeutics PLX Stock Holding History

Steward Partners Investment Advisory’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25	Closed	-$56	–	4435
2025 Q3	$56	Buy	+25	New	+$41	﹤0.01%	4208
2021 Q4	–	Sell	-1,000	Closed	-$1K	–	3284
2021 Q3	$1K	Hold	1,000	–	–	﹤0.01%	3098
2021 Q2	$2K	Hold	1,000	–	–	﹤0.01%	6889
2021 Q1	$4.46K	Hold	1,000	–	–	﹤0.01%	3036
2020 Q4	$4K	Buy	+1,000	New	+$3.58K	﹤0.01%	2579
2020 Q3	–	Sell	-200	Closed	-$1K	–	2822
2020 Q2	$1K	Hold	200	–	–	﹤0.01%	2596
2020 Q1	$0	Hold	200	–	–	﹤0.01%	2648
2019 Q4	$0	Hold	200	–	–	﹤0.01%	2705
2019 Q3	$0	Hold	200	–	–	﹤0.01%	2730
2019 Q2	$0	Buy	+200	New	+$845	﹤0.01%	2673
2018 Q4	–	Sell	-200	Closed	-$1K	–	1770
2018 Q3	$1K	Hold	200	–	–	﹤0.01%	2514
2018 Q2	$1K	Hold	200	–	–	﹤0.01%	2374
2018 Q1	$1K	Buy	+200	New	+$1.32K	﹤0.01%	2158

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Steward Partners Investment Advisory's PLX Position: Q4 2025 in Review

Steward Partners Investment Advisory sold out of Protalix BioTherapeutics (PLX) in Q4 2025, closing a stake of 25 shares — an estimated $56 sold.

Steward Partners Investment Advisory first reported a position in PLX in Q1 2018 and held it in 13 quarters. The position peaked at $4.46K in Q1 2021. 83 funds tracked by Wall St. Rank hold PLX as of Q4 2025.

Steward Partners Investment Advisory reported no remaining Protalix BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Steward Partners Investment Advisory sold 25 Protalix BioTherapeutics shares in Q4 2025, an estimated $56.
Steward Partners Investment Advisory first reported a position in Protalix BioTherapeutics in Q1 2018 and held it in 13 quarters.
Steward Partners Investment Advisory's Protalix BioTherapeutics position peaked at $4.46K in Q1 2021.
83 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2025.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2025, filed 12 Feb 2026.